Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02235493 · ClinicalTrials.gov registry record

Non-interventional Substudy of ALX-HPP-502 to Assess Natural History of Patients With Juvenile-onset HPP Who Served as Historical Controls in ENB-006-09

A clinical trial, sponsored by Alexion Pharmaceuticals.

Completed
Registry status
6
Enrollment target

NCT02235493 is a clinical trial that has completed, run by Alexion Pharmaceuticals. The registered enrollment target is 6 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02235493 has completed, sponsored by Alexion Pharmaceuticals.

COMPLETED
Registry status
6 participants
Enrollment target

Study Summary

The purpose of this study is to characterize the natural history of HPP in patients with Juvenile-onset HPP who served as historical controls in ENB-006-09.

Interventions

  • BIOLOGICAL Retrospective Case Only

Trial Details

FieldValue
Enrollment Target 6 participants
Start Date 2014-08
Est. Completion 2014-09

Sponsor

Alexion Pharmaceuticals

162 total trials

What the Registry Record Tells You About NCT02235493

The ClinicalTrials.gov registry entry for NCT02235493 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alexion Pharmaceuticals, which has 162 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Retrospective Case Only is the first listed.

NCT02235493 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02235493 about?

NCT02235493 is a clinical study titled "Non-interventional Substudy of ALX-HPP-502 to Assess Natural History of Patients With Juvenile-onset HPP Who Served as Historical Controls in ENB-006-09". The purpose of this study is to characterize the natural history of HPP in patients with Juvenile-onset HPP who served as historical controls in ENB-006-09.

What is the current status of trial NCT02235493?

This trial is currently completed. The enrollment target is 6 participants. The study started on 2014-08. Estimated completion is 2014-09.

What interventions are being tested in trial NCT02235493?

The interventions under investigation include: Retrospective Case Only (BIOLOGICAL).

Who is sponsoring clinical trial NCT02235493?

This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.